Thuja Capital

Alesta Therapeutics is a biotechnology company dedicated to developing innovative therapies for cancer treatment. The company focuses on small molecule programs that target synthetic lethal metabolic dependencies within cancer cells. By addressing control mechanisms involved in chronic stress response pathways critical for cancer cell survival, Alesta Therapeutics aims to create therapeutic approaches that can effectively inhibit pathways essential for cancer growth. This targeted strategy seeks to offer new treatment options for patients, ultimately enhancing cancer care by translating novel scientific insights into practical medical solutions.

Alveron Pharma is a biotechnology company focused on developing treatments for hemorrhagic stroke, a condition with significant unmet medical needs. Their lead drug candidate, OKL-1111, has shown promise in reducing hematoma expansion in preclinical mouse models of intracranial hemorrhage. This drug is designed as an injection solution that is ready to use, aiming to eliminate the need for complex pre-treatment processes. Alveron Pharma's technology centers around cyclodextrins and procoagulant cyclodextrins, which are used to create anticoagulant reversal drugs. These innovations target excessive bleeding in various contexts, including hemophilia, trauma, surgery, and bleeding related to the use of anticoagulants, thereby providing both acute and long-term therapeutic options for thromboembolic disorders.

Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.

Artica Therapeutics is a biotechnology company focused on the research and development of innovative therapies aimed at treating severe autoimmune and inflammatory disorders. The company employs label-free cellular-based screening methods, which facilitate the rapid advancement of drug candidates through the development process. This approach enables healthcare professionals to more effectively address the needs of patients suffering from these complex conditions. Additionally, Artica Therapeutics is involved in the development of medical devices and pharmaceutical processes, underscoring its commitment to advancing healthcare solutions.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

Gradient Denervation Technologies is a medical device company based in Paris, France, founded in 2019. It specializes in the development of an endovascular catheter-based technology designed to treat pulmonary hypertension. The device focuses on performing pulmonary artery denervation, which aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics. This innovative approach offers a minimally invasive solution for managing pulmonary hypertension and is built upon prior research and intellectual property developed at Stanford University. The company aims to provide the healthcare sector with a device that delivers consistent and long-lasting results for patients suffering from this condition.

FundaMental Pharma is a neuroscience company focused on developing innovative therapies to address neurological diseases. The company is engaged in the creation of neuroprotective molecular spacers aimed at preventing neurodegeneration in the brain. By utilizing peptides and gene therapy techniques, FundaMental Pharma works on diagnosing genetic polymorphisms and specializes in a new class of drugs designed to combat conditions that are currently untreatable. Their research and development efforts are concentrated on providing pharmacological solutions for patients suffering from challenging neurological conditions. With a portfolio positioned at the preclinical stage, FundaMental Pharma is dedicated to advancing treatments that could potentially improve the lives of individuals affected by these disorders.

AstriVax is a biotechnology company focused on developing innovative vaccines that address significant challenges in the field of vaccinology. The company aims to achieve initial clinical validation of its platform technology, which is designed to create a diverse pipeline of vaccines. AstriVax's vaccine candidates are engineered to minimize cold chain requirements, making them more accessible and easier to distribute. Additionally, these vaccines are intended to provide broad and long-lasting protection against a variety of viruses and pathogens, thereby enhancing treatment options within the healthcare sector.

InnoSIGN is a company focused on mRNA-based pathway activity profiling technology that aims to advance precision medicine by enhancing understanding of disease mechanisms. By leveraging a vast library of pathway activity profiles, InnoSIGN seeks to improve diagnostics and drug discovery processes. The company provides researchers with qPCR tests designed for decentralized use, which are available through its service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN aspires to transform the landscape of medical research and treatment by delivering more accurate insights into the causes of diseases.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

Alveron Pharma is a biotechnology company focused on developing treatments for hemorrhagic stroke, a condition with significant unmet medical needs. Their lead drug candidate, OKL-1111, has shown promise in reducing hematoma expansion in preclinical mouse models of intracranial hemorrhage. This drug is designed as an injection solution that is ready to use, aiming to eliminate the need for complex pre-treatment processes. Alveron Pharma's technology centers around cyclodextrins and procoagulant cyclodextrins, which are used to create anticoagulant reversal drugs. These innovations target excessive bleeding in various contexts, including hemophilia, trauma, surgery, and bleeding related to the use of anticoagulants, thereby providing both acute and long-term therapeutic options for thromboembolic disorders.

EsoBiotec is a Belgian biotechnology company dedicated to the discovery of innovative cancer therapies. The firm specializes in immunotherapies that aim to empower the human body to combat cancer through in vivo cell engineering. EsoBiotec focuses on developing cost-effective drugs and therapeutics, ensuring that patients have access to essential cancer treatments at lower costs. By prioritizing accessibility, the company seeks to improve the overall effectiveness of cancer care and enhance patient outcomes.

Kinetyx Sciences Inc., established in 2020 and headquartered in Calgary, Canada, specializes in developing in-shoe sensor technology for various sports and performance applications. Their innovative sensory insoles collect high-fidelity data at the point where the foot and ground intersect, providing laboratory-quality data in real-world environments. This data enables users to gain unique insights into their movements, enhancing performance, aiding injury prevention, and facilitating a safe return from injuries.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

NutriLeads is a startup focused on developing innovative nutritional ingredients with clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to support physiological processes and modulate the gut microbiome. NutriLeads collaborates with industry partners to identify promising lead ingredients, create sustainable and commercially viable production processes, and initiate scientific and clinical programs that validate the health effects of its offerings. By doing so, NutriLeads aims to enhance nutritional health innovation in the food industry, ultimately providing consumers and patients with access to dietary supplements and specialized functional food and beverage products that deliver these benefits.

Indigo Diabetes, established in 2016 and headquartered in Ghent, Belgium, specializes in developing innovative, non-invasive glucose monitoring solutions. The company's flagship product is an invisible, photonics-based sensor that is inserted under the skin, continuously measuring blood sugar levels, thereby eliminating the need for traditional finger pricks. Indigo Diabetes aims to enhance the lives of people with diabetes by providing accurate glucose monitoring with an improved user experience.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Mellon Medical B.V., established in 2013 and based in Nijmegen, the Netherlands, specializes in the development and marketing of innovative medical suturing tools designed for surgeons. The company focuses on enhancing healthcare treatment procedures by providing advanced surgical instruments that enable single-handed stitching. This unique capability allows medical specialists to perform efficient and effective suturing of tubular and layered structures, ultimately aiming to improve patient outcomes during surgical procedures. Through its commitment to innovation in surgical technology, Mellon Medical seeks to support healthcare professionals in delivering high-quality care.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

NutriLeads is a startup focused on developing innovative nutritional ingredients with clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to support physiological processes and modulate the gut microbiome. NutriLeads collaborates with industry partners to identify promising lead ingredients, create sustainable and commercially viable production processes, and initiate scientific and clinical programs that validate the health effects of its offerings. By doing so, NutriLeads aims to enhance nutritional health innovation in the food industry, ultimately providing consumers and patients with access to dietary supplements and specialized functional food and beverage products that deliver these benefits.

Indigo Diabetes, established in 2016 and headquartered in Ghent, Belgium, specializes in developing innovative, non-invasive glucose monitoring solutions. The company's flagship product is an invisible, photonics-based sensor that is inserted under the skin, continuously measuring blood sugar levels, thereby eliminating the need for traditional finger pricks. Indigo Diabetes aims to enhance the lives of people with diabetes by providing accurate glucose monitoring with an improved user experience.

MiLabs is a manufacturer specializing in high-end molecular imaging solutions designed for biomedical research. The company develops multimodal and integrated imaging systems, including micro-PET, micro-SPECT, micro-CT scanners, and optical tomography systems. These advanced technologies are utilized by universities, biomedical institutions, and pharmaceutical companies for the diagnosis of various diseases, including diabetes, cancer, and neurodegenerative disorders. MiLabs focuses on creating user-friendly diagnostic systems that enhance efficiency and streamline workflows, thereby contributing to the global advancement of diagnostic techniques in the medical field.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

NutriLeads is a startup focused on developing innovative nutritional ingredients with clinically proven health benefits. The company specializes in precision prebiotic fibers derived from crops, which are designed to support physiological processes and modulate the gut microbiome. NutriLeads collaborates with industry partners to identify promising lead ingredients, create sustainable and commercially viable production processes, and initiate scientific and clinical programs that validate the health effects of its offerings. By doing so, NutriLeads aims to enhance nutritional health innovation in the food industry, ultimately providing consumers and patients with access to dietary supplements and specialized functional food and beverage products that deliver these benefits.

FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.

Hemics is a medical device company focused on improving the quality of life for patients with Rheumatoid Arthritis (RA). The company specializes in developing imaging devices that assist rheumatologists in monitoring and treating this condition. Hemics' devices utilize patented Optical Inflammation Detection technology, which offers a non-invasive, rapid, and objective means of quantifying inflammation, a critical factor in managing RA. Their imaging apparatus enables operator-independent assessment of disease activity in the joints, thereby facilitating more accurate treatment decisions. Founded as a spin-out from Royal Philips Electronics, Hemics leverages innovative technology to enhance the effectiveness of rheumatoid arthritis management.

Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.

EnCare Biotech B.V. is a biopharmaceutical company based in Utrecht, the Netherlands, established in 2014. It specializes in the development of therapeutic monoclonal antibodies, specifically targeting the EDA fragment of fibronectin, to prevent chronic heart failure following acute myocardial infarction. The company’s lead product focuses on providing innovative therapies to help healthcare professionals mitigate the risks of heart failure in patients. EnCare Biotech leverages a strong scientific foundation, collaborating with academic institutions and experts in various fields, including manufacturing, regulatory affairs, and clinical development. The management team possesses extensive experience in business development and finance, enabling the company to establish valuable partnerships and navigate complex regulatory environments. EnCare operates under a lean business model, maintaining core functions in-house while outsourcing operational activities to top-tier external providers, ensuring high standards of quality and efficiency in its development processes.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

Mellon Medical B.V., established in 2013 and based in Nijmegen, the Netherlands, specializes in the development and marketing of innovative medical suturing tools designed for surgeons. The company focuses on enhancing healthcare treatment procedures by providing advanced surgical instruments that enable single-handed stitching. This unique capability allows medical specialists to perform efficient and effective suturing of tubular and layered structures, ultimately aiming to improve patient outcomes during surgical procedures. Through its commitment to innovation in surgical technology, Mellon Medical seeks to support healthcare professionals in delivering high-quality care.

Hemics is a medical device company focused on improving the quality of life for patients with Rheumatoid Arthritis (RA). The company specializes in developing imaging devices that assist rheumatologists in monitoring and treating this condition. Hemics' devices utilize patented Optical Inflammation Detection technology, which offers a non-invasive, rapid, and objective means of quantifying inflammation, a critical factor in managing RA. Their imaging apparatus enables operator-independent assessment of disease activity in the joints, thereby facilitating more accurate treatment decisions. Founded as a spin-out from Royal Philips Electronics, Hemics leverages innovative technology to enhance the effectiveness of rheumatoid arthritis management.

TheraSolve NV is a medical technology company focused on enhancing medication adherence through innovative solutions. The company has developed a patented technology platform designed to motivate patients across diverse populations to take their medications as prescribed and engage in health-promoting activities. One of its key products, the Memopatch, is a skin patch that supports and reminds patients when to take their medications, thereby improving compliance with treatment regimens. TheraSolve aims to provide user-friendly and cost-effective tools that address the critical challenge of medication adherence in healthcare.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.

FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.

Cavadis is a Dutch biomedical company specializing in cardiovascular risk assessment. The company focuses on developing prognostic tests that identify patients at risk of cardiovascular diseases, including heart attacks and strokes. Cavadis has identified several novel biomarkers that are predictive of cardiovascular events and outperform traditional risk factors. Their aim is to create clinically meaningful risk stratification tools that enable physicians to personalize treatment plans, ultimately leading to improved patient outcomes. Through their innovative approach, Cavadis seeks to enhance the accuracy of cardiovascular risk assessment and support healthcare providers in delivering tailored medical care.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics specifically for pets and livestock. It has a proprietary platform that supports the creation of innovative treatments targeting various viral diseases. The company is advancing its pipeline of clinical and development stage candidates, including drugs intended for feline herpes and feline immunodeficiency virus. Through its research and development efforts, Okapi aims to provide veterinarians with the latest antiviral treatments, enhancing the standards of care for animal health. Targeting both companion animals and livestock, Okapi Sciences is positioned to make significant contributions to veterinary medicine with its novel technologies and strong academic partnerships.

Bioceros B.V. is a biopharmaceutical research and development contract organization based in Utrecht, the Netherlands, founded in 2003. The company specializes in the early pre-clinical development of recombinant proteins, particularly monoclonal antibodies. Bioceros provides a comprehensive range of technical and scientific services, including assay development, molecular biology, cell biology, immunology, protein expression, upscaling, fermentation, protein purification, and consulting. These services are aimed at biotech companies, academic institutions, and pharmaceutical firms, enabling them to access fully integrated programs from DNA to drug product. This approach supports the advancement of medicinal products and ultimately aids in addressing patient needs.

Cavadis is a Dutch biomedical company specializing in cardiovascular risk assessment. The company focuses on developing prognostic tests that identify patients at risk of cardiovascular diseases, including heart attacks and strokes. Cavadis has identified several novel biomarkers that are predictive of cardiovascular events and outperform traditional risk factors. Their aim is to create clinically meaningful risk stratification tools that enable physicians to personalize treatment plans, ultimately leading to improved patient outcomes. Through their innovative approach, Cavadis seeks to enhance the accuracy of cardiovascular risk assessment and support healthcare providers in delivering tailored medical care.

Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics specifically for pets and livestock. It has a proprietary platform that supports the creation of innovative treatments targeting various viral diseases. The company is advancing its pipeline of clinical and development stage candidates, including drugs intended for feline herpes and feline immunodeficiency virus. Through its research and development efforts, Okapi aims to provide veterinarians with the latest antiviral treatments, enhancing the standards of care for animal health. Targeting both companion animals and livestock, Okapi Sciences is positioned to make significant contributions to veterinary medicine with its novel technologies and strong academic partnerships.

Galapagos NV is a clinical-stage biotechnology company based in Mechelen, Belgium, that focuses on discovering, developing, and commercializing small molecule medicines. The company’s clinical programs include filgotinib, a JAK1 inhibitor undergoing trials for multiple conditions such as rheumatoid arthritis and Crohn’s disease, as well as GLPG1690, an autotaxin inhibitor in trials for idiopathic pulmonary fibrosis and systemic sclerosis. Additionally, Galapagos is developing GLPG1205, a GPR84 inhibitor for idiopathic pulmonary fibrosis, and GLPG1972 for osteoarthritis. The company also explores Toledo molecules for inflammation. Galapagos has established collaborations with several pharmaceutical companies, including Gilead Sciences and AbbVie. Founded in 1999, Galapagos aims to address diseases with high unmet medical needs and improve patient outcomes globally.

EpiCept Corporation, headquartered in Englewood Cliffs, New Jersey, with a subsidiary in Munich, Germany, specializes in the development of innovative pharmaceutical products aimed at treating pain and cancer. The company focuses on creating safe and effective prescription pain management solutions that utilize a topical delivery system, distinguishing itself from traditional systemic or transdermal methods. EpiCept is committed to exploring partnerships for co-marketing, co-promotion, licensing, and distribution with third-party collaborators to expand its reach in the market. The company's products are supported by a robust patent portfolio, reflecting its dedication to protecting its innovations and capitalizing on the significant market potential of its offerings.

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

Drug Abuse Sciences develops and commercializes therapies for the treatment of alcohol and drug addictions. It offers Naltrexone Depot, a sustained-release formulation of Naltrexone for the treatment of alcohol and opiate addictions; DAS-431 for the treatment of cocaine addiction; and Buprenorphine Depot, a sustained-release formulation of buprenorphine for the treatment of heroin and various opiate addictions. Drug Abuse Sciences is based in Menlo Park, California.

Ingenium Pharmaceuticals AG is discovers and develops molecules for the treatment of neuronal and autoimmune diseases.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Curacyte GmbH is a biopharmaceutical company based in Munich, Germany, founded in 2001. It specializes in developing innovative therapeutics for acute and critical care, focusing on areas such as hematology, antithrombosis, and oncology. The company's research efforts aim to create advanced biopharmaceutics that address urgent medical needs, providing new treatment options for patients with critical diseases.

Breonics is a biomedical research and development company focused on advancing organ and tissue transplantation. Its flagship innovation, Exsanguinous Metabolic Support (EMS) technology, significantly expands the criteria for kidney donors by including patients who would typically be ineligible. This groundbreaking technology maintains the oxidative metabolism and functionality of organs and tissues while they are isolated from the body, thereby extending the recovery time for organs. By addressing the technical challenges associated with organ donation, Breonics aims to more than double the number of transplantable kidneys available worldwide, ultimately enhancing the capabilities of healthcare practitioners in the field of organ transplants.

Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets biological products for the biosurgical and immunotherapy markets.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.

Vernalis Limited is a commercial stage pharmaceutical company based in Cambridge, United Kingdom, focused on the research, development, and commercialization of pharmaceutical products for various medical disorders. The company offers several products, including Tuzistra XR for the U.S. prescription cough-cold market, Moxatag, a once-daily amoxicillin formulation for treating tonsillitis and pharyngitis, and frovatriptan for acute migraine treatment. Vernalis engages in developing and commercializing additional products through licensing agreements, emphasizing its strategy of combining internal research with collaborations with global pharmaceutical companies. Its research laboratories employ advanced techniques such as fragment-based approaches, structural biology, and medicinal chemistry to facilitate drug discovery. Established in 1988, Vernalis operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.